View ValuationStemRIM 将来の成長Future 基準チェック /06現在、 StemRIMの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長38.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Price Target Changed • Mar 14Price target decreased by 25% to JP¥900Down from JP¥1,200, the current price target is provided by 1 analyst. New target price is 57% above last closing price of JP¥574. Stock is down 47% over the past year. The company is forecast to post a net loss per share of JP¥21.20 compared to earnings per share of JP¥2.80 last year.お知らせ • Jun 19StemRIM Provides Earnings Guidance for the Year Ending July 31, 2023StemRIM provided earnings guidance for the year ending July 31, 2023. The company expects operating revenue of ¥2,350 million, operating income of ¥146 million, net income of ¥170 million or ¥2.84 per share.Price Target Changed • Nov 16Price target increased to JP¥1,240Up from JP¥1,000, the current price target is provided by 1 analyst. New target price is 35% above last closing price of JP¥920. Stock is up 68% over the past year. The company posted a net loss per share of JP¥32.91 last year.Price Target Changed • Apr 27Price target increased to JP¥1,400Up from JP¥1,200, the current price target is provided by 1 analyst. New target price is 91% above last closing price of JP¥733. Stock is down 8.4% over the past year. The company posted a net loss per share of JP¥10.02 last year.Price Target Changed • Oct 01Price target increased to JP¥1,000Up from JP¥900, the current price target is provided by 1 analyst. New target price is 47% above last closing price of JP¥682. Stock is down 20% over the past year.Price Target Changed • Apr 27Price target decreased to JP¥1,250Down from JP¥1,350, the current price target is provided by 1 analyst. New target price is 58% above last closing price of JP¥792. Stock is up 70% over the past year.すべての更新を表示Recent updates分析記事 • Jun 18We're Not Very Worried About StemRIM's (TSE:4599) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...お知らせ • Jun 17StemRIM Announces Patent Registration (Australia) for Redasemtide, as an Additional Therapeutic Indication of Cartilage DisordersStemRIM Inc. announced that a patent will soon be registered in Australia for the application related to the novel treatment of cartilage disorders (namely traumatic cartilage defect of joint, osteoarthritis, and osteochondritis dissecans) utilizing the peptide drug developed from the "Regeneration-Inducing MedicineTM" development candidate Redasemtide (HMGB1 fragment peptide). Title of Invention Therapeutic agent for cartilage disorder. Region Australia. Application No. 2019367943. Registration No. To be determined . Applicant StemRIM, Osaka University This patent is intended to expand the indications for Redasemtide, which is currently under development, and believe that the granting of this patent will ensure the possibility of developing a drug for cartilage disorders (namely traumatic cartilage defect of joint, osteoarthritis, and osteochondritis dissecans) in Australia. Cartilage disorders cause pain and functional impairment of the joint due to damage or degeneration of cartilage. Because cartilage has limited selfrepair capacity, such disorders tend to become chronic and progressive. It has been confirmed that intravenous administration of Redasemtide mobilizes bone marrow-derived mesenchymal stem cells (MSCs) into the bloodstream and promotes their accumulation at sites of tissue injury. Through this mechanism, Redasemtide is considered to facilitate tissue repair and regeneration in areas of cartilage damage within the knee joint. With its intravenous route of administration, which imposes a relatively low burden on patients, Redasemtide is anticipated to serve as a highly useful therapeutic option in clinical practice.お知らせ • Jun 16StemRIM Inc Announces Patent Registration In Russia For Redasemtide As Therapeutic Drug For Fatty Liver And Non-Alcoholic SteatohepatitisStemRIM Inc. announced that a medical use patent for the Regeneration-Inducing MedicineTM development candidate, Redasemtide, indicated for fatty liver and non-alcoholic steatohepatitis, will soon be registered in Russia. Title of Invention: Therapeutic drug for fatty liver and non-alcoholic steatohepatitis. Region: Russia. Application No.: 2024111536. Registration No.: To be determined. Applicant: StemRIM Inc., Osaka University, Niigata University. This patent is intended to expand the indications for Redasemtide, which is currently under development. Fatty liver is a condition in which excess fat accumulates in the liver. Non-alcoholic steatohepatitis (NASH) is a progressive fatty liver disease caused by factors other than alcohol consumption characterized by inflammation and fibrosis of the liver, which, if left untreated, can lead to cirrhosis or liver cancer. Both fatty liver and NASH are expected to see an increase in patient numbers due to the rising prevalence of obesity and diabetes. However, there are currently no effective drug treatments available, and dietary and exercise therapy remain the main approaches. The development of new therapeutic drugs and regenerative medicine is urgently needed. The impact on the financial performance for the fiscal year ending July 31, 2026, is insignificant. The terms "fatty liver" and "non-alcoholic steatohepatitis (NASH)" have been renamed to "steatotic liver disease (SLD)" and "metabolic dysfunction associated steatohepatitis (MASH)," respectively.New Risk • Mar 11New major risk - Revenue and earnings growthEarnings have declined by 30% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 30% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (6.7% average weekly change).New Risk • Jan 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.3b net loss in 3 years). Share price has been volatile over the past 3 months (5.4% average weekly change).お知らせ • Jan 06StemRIM to Report Q2, 2026 Results on Mar 11, 2026StemRIM announced that they will report Q2, 2026 results on Mar 11, 2026New Risk • Dec 15New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥15.5b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.3b net loss in 3 years). Market cap is less than US$100m (JP¥15.5b market cap, or US$99.9m).Board Change • Nov 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. Founder, Chief Scientific Officer & Director Katsuto Tamai was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Oct 28StemRIM to Report Q1, 2026 Results on Dec 10, 2025StemRIM announced that they will report Q1, 2026 results on Dec 10, 2025お知らせ • Sep 10StemRIM, Annual General Meeting, Oct 22, 2025StemRIM, Annual General Meeting, Oct 22, 2025.お知らせ • Aug 09StemRIM to Report Fiscal Year 2025 Results on Sep 10, 2025StemRIM announced that they will report fiscal year 2025 results on Sep 10, 2025お知らせ • Jun 03StemRIM to Report Q3, 2025 Results on Jun 11, 2025StemRIM announced that they will report Q3, 2025 results on Jun 11, 2025Board Change • May 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Outside Director Noriko Sawai was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Apr 09We're Interested To See How StemRIM (TSE:4599) Uses Its Cash Hoard To GrowEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • Apr 02StemRIM Inc. Announces the Interim Analysis Results for the Global Phase 2B Clinical Trial in Patients with Acute Ischemic StrokeStemRIM Inc. announced that the interim analysis results for the global Phase 2b clinical trial of Redasemtide, which was previously out-licensed from company to Shionogi & Co. Ltd. for the treatment of acute ischemic stroke (AIS). This clinical trial is being conducted in 18 countries worldwide, including Japan, the United States, and Europe, to evaluate the efficacy and safety of Redasemtide in AIS patients who are not eligible for endovascular recanalization therapy. The trial consists of 3 cohorts, with patients receiving Redasemtide at a dose of 1.5 mg/kg, Redasemtide at an dose of 0.75 mg/kg, or a placebo for 5 days. With advances in medical technology, the treatment paradigm for AIS has undergone significant changes, and the proportion of patients eligible for treatment with endovascular recanalisation therapy has been rapidly increasing. To adapt to these changes and enable broader patient access to Redasemtide after its market approval, conducted an interim futility analysis by dose group in AIS patients for whom endovascular reperfusion therapy could not be performed. In this interim analysis, a predefined futility criterion was established. For each dose group, if the results met the futility criterion compared to the placebo group, the study would be discontinued for that group; if not, it would be continued. To maintain blinding, an independent evaluation committee assessed the data and provided recommendations to Shionogi regarding the continuation or discontinuation of each dose group. While Redasemtide (1.5 mg/kg) group was originally selected as the expected efficacious dose at the start of the trial, the inclusion of Redasemtide (0.75 mg/kg) group was mandated by regulatory authorities. The outcome of this interim analysis falls within the anticipated range. With the discontinuation of the lower dose group, the required number of subjects will be reduced, and further progress in the study is expected moving forward. Going forward, the target number of subjects will be redefined to include the additional cohort; however, the overall study duration is not expected to be extended. The results of this interim analysis hold significant importance in the clinical development of this investigational drug for AIS, and the company are very pleased with the outcome. At this time, there is no impact on the financial results for the fiscal year ending July 31, 2025.New Risk • Mar 11New major risk - Revenue and earnings growthEarnings have declined by 31% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 31% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (5.9% average weekly change).お知らせ • Jan 30StemRIM to Report Q2, 2025 Results on Mar 12, 2025StemRIM announced that they will report Q2, 2025 results on Mar 12, 2025New Risk • Dec 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Earnings are forecast to decline by an average of 1.8% per year for the foreseeable future. Minor Risk Share price has been volatile over the past 3 months (5.4% average weekly change).お知らせ • Oct 29StemRIM to Report Q1, 2025 Results on Dec 11, 2024StemRIM announced that they will report Q1, 2025 results on Dec 11, 2024分析記事 • Oct 04StemRIM (TSE:4599) Is In A Strong Position To Grow Its BusinessEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • Sep 11StemRIM, Annual General Meeting, Oct 30, 2024StemRIM, Annual General Meeting, Oct 30, 2024.お知らせ • Jul 27StemRIM to Report Fiscal Year 2024 Results on Sep 11, 2024StemRIM announced that they will report fiscal year 2024 results on Sep 11, 2024New Risk • Jun 17New major risk - Revenue sizeThe company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.7b net loss in 3 years). Share price has been volatile over the past 3 months (5.6% average weekly change). Shareholders have been diluted in the past year (2.5% increase in shares outstanding).お知らせ • Apr 03StemRIM to Report Q3, 2024 Results on Jun 12, 2024StemRIM announced that they will report Q3, 2024 results on Jun 12, 2024分析記事 • Mar 20StemRIM's (TSE:4599) Earnings Seem To Be PromisingThe market seemed underwhelmed by the solid earnings posted by StemRIM ( TSE:4599 ) recently. Our analysis suggests...Price Target Changed • Mar 14Price target decreased by 25% to JP¥900Down from JP¥1,200, the current price target is provided by 1 analyst. New target price is 57% above last closing price of JP¥574. Stock is down 47% over the past year. The company is forecast to post a net loss per share of JP¥21.20 compared to earnings per share of JP¥2.80 last year.お知らせ • Mar 13StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic CardiomyopathyStemRIM Inc. announced that a clinical trial plan for Phase 2 investigator-initiated clinical trial, targeting ischemic cardiomyopathy using Redasemtide, has been submitted to the Pharmaceuticals and Medical Devices Agency (PMDA) by Osaka University. Redasemtide is a drug under development that has been licensed out to Shionogi & Co. Ltd. This clinical trial will be initiated with the submission of this clinical trial plan notification. This clinical trial will be conducted as an investigator-initiated clinical trials at Osaka University Hospital and several other facilities. The main objective of this clinical trial is to evaluate the efficacy and safety of Redasemtide in patients with ischemic cardiomyopath who have undergone coronary artery bypass grafting. This clinical trial will evaluate various cardiac function tests such as echocardiography at 52 weeks after treatment with either Redasemtide or placebo (10 patients each) for 5 days. Redasemtide are a completely new concept in medicine that induces functional regeneration of organs and tissues damaged by injury or disease. The ectodermal mesenchymal stem cells induced by administration of Redasemtide can differentiate into diverse tissues and are expected to be effective in a variety of disease areas, including ischemic cardiomyiology. Furthermore, as it is administered through intravenous infusion and does not involve the use of live cells, this pharmaceutical product is industrially producible. Unlike traditional regenerative medical products that utilize live cells, it avoids quality control issues during manufacturing and product transport. It is anticipated to have a cost advantage and widespread adoption due to its simple administration method. In clinical trials to date, the safety and efficacy of Redasemtide have been confirmed in dystrophic epidermolysis bullosa (add additional Phase 2 clinical trial ongoing at Osaka University Hospital and other institutions), acute ischemic stroke (global Phase 2b clinical trial ongoing in Japan, the United States, and Europe), knee osteoarthritis (Phase 2 investigator-initiatedclinical trial completed at Hirosaki University Hospital), and chronic liver disease (Phase 2 investigator-in initiated clinical trial l completed at Niigata University Medical and Dental Hospital). Ischemic cardiomyopathy will be the 5th indication for Redasemtide in a Phase 2 clinical trial. The impact on the financial performance for the fiscal year ending July 31, 2024, is nothing. Nevertheless, believe it contributes to the medium to long-term improvement of overall performance.お知らせ • Feb 01StemRIM Inc. Announces Patent Registration (Russia) for the Use of the HMGB1 Fragment Peptide, as an Additional Therapeutic Indication of Cartilage DisordersStemRIM Inc. announced that a patent has been registered in Russia for the application related to the novel treatment of cartilage disorders (traumatic cartilage deficiency syndrome, osteoarthritis, disseverance osteochondritis, etc.) utilizing the peptide drug developed from the "Regeneration-Inducing MedicineTM" development candidate Redasemtide (HMGB1 fragment peptide). Title of Invention: Therapeutic agent for traumatic cartilage deficiency syndrome, osteearthritis, disseverance Osteochondritis. Region.: Russia. Application No. 2021114359. Registration No. To be determined. Applicant. StemRIM, Osaka University. This patent is intended to expand the indications for Redasemtide, which is currently under development, and believe that the granting of this patent will ensure the possibility of developing a drug for cartilage disorders (traumatic cart cartilage deficiency syndrome, osteOarthritis, disseverance boneochondritis, etc.) in Russia. To date, the company have been granted many patents for HMGB1 fragment peptides (including Redasemtide) in Japan, the U.S., Europe, and other countries around the world, including substance patents and medical use patents. The impact on the financial performance for the fiscal year ending July 31, 2024, is insignificant.お知らせ • Jan 28StemRIM to Report Q2, 2024 Results on Mar 13, 2024StemRIM announced that they will report Q2, 2024 results on Mar 13, 2024お知らせ • Oct 29StemRIM to Report Q1, 2024 Results on Dec 13, 2023StemRIM announced that they will report Q1, 2024 results on Dec 13, 2023お知らせ • Sep 13StemRIM, Annual General Meeting, Oct 25, 2023StemRIM, Annual General Meeting, Oct 25, 2023.お知らせ • Sep 05StemRIM Announces Patent Registration (China) for the Use of Redasemtide as an Additional Treatment for Cardiomyopathy and Old Myocardial InfarctionStemRIM announces that a medical use patent for the "Regeneration- Inducing MedicineTM" development candidate, Redasemtide, indicated for cardiomyopathy, old myocardial infarction, and chronic heart failure associated with them, will soon be registered in China. This patent is intended to expand the indications for Redasemtide, which is currently underdevelopment, and believe that the granting of this patent will ensure the possibility of developing a drug for cardiomyopathy, old myocardial infarction, and chronic heart failure inChina. To date, it have been granted many patents for HMGB1 fragment peptides (including Redasemtide) in Japan, the U.S., Europe, and other countries around the world, including substance patents and medical use patents. The impact on the financial performance for the fiscal year ending July 31, 2024, is insignificant.お知らせ • Aug 01StemRIM Inc. Announces the First Administration of Global Late Phase 2 Clinical Trials for Redasemtide Targeting Acute Ischemic Stroke (Japan)StemRIM Inc. announced that Shionogi & Co. Ltd. has notified that the first patient has been administered of the global late phase 2 clinical trial for Redasemtide targeting acute ischemic stroke in Japan. This clinical trial is a global late phase 2 clinical trial, planned to be conducted in 19 countriesworldwide, including Japan, the United States, and Europe. It aims to evaluate the effectiveness and safety of administering Redasemtide to 627 patients with acute ischemic stroke, aged 18 years and above, within 25 hours of symptom onset.お知らせ • Jul 26StemRIM Inc. Announces Commencement of Global Late Phase 2 Clinical Trial for Redasemtide in Patients with Acute Ischemic Stroke in the Europe and ChinaStemRIM Inc. announced the commencement, from July 25, 2023, of a global late Phase 2 clinical trial for Redasemtide in patients with acute ischemic stroke in the Europe and China. Shionogi &Co. Ltd. submitted the Clinical Trial Plan Notification for the global Phase 2 clinical trial to the European Medicines Agency on March 31, 2023, and to the National Medical Products Administration in China on April 28, 2023. Originally, a global Phase 3 trial was planned, but a global late Phase 2 trial was chosen instead for dose setting. The trial has already been underway in Japan and the United States, and it has just started in Europe and China. This development is progressing as planned and is not expected to have any impact on the financial performance for the fiscal year ending July 31, 2023. However, the company believe that it will contribute to the improvement of its performance in the medium to long term.お知らせ • Jul 22StemRIM to Report Fiscal Year 2023 Results on Sep 13, 2023StemRIM announced that they will report fiscal year 2023 results on Sep 13, 2023お知らせ • Jun 19StemRIM Provides Earnings Guidance for the Year Ending July 31, 2023StemRIM provided earnings guidance for the year ending July 31, 2023. The company expects operating revenue of ¥2,350 million, operating income of ¥146 million, net income of ¥170 million or ¥2.84 per share.Reported Earnings • Jun 16Third quarter 2023 earnings released: EPS: JP¥31.50 (vs JP¥8.31 loss in 3Q 2022)Third quarter 2023 results: EPS: JP¥31.50 (up from JP¥8.31 loss in 3Q 2022). Net income: JP¥1.80b (up JP¥2.29b from 3Q 2022). Revenue is expected to decline by 40% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Japan are expected to grow by 9.1%. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings.お知らせ • Jan 06StemRIM to Report Q2, 2023 Results on Mar 08, 2023StemRIM announced that they will report Q2, 2023 results on Mar 08, 2023Price Target Changed • Nov 16Price target increased to JP¥1,240Up from JP¥1,000, the current price target is provided by 1 analyst. New target price is 35% above last closing price of JP¥920. Stock is up 68% over the past year. The company posted a net loss per share of JP¥32.91 last year.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Outside Director Tadahiro Nagai was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Nov 11Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Outside Director Tadahiro Nagai was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 02Full year 2022 earnings released: JP¥32.91 loss per share (vs JP¥10.02 loss in FY 2021)Full year 2022 results: JP¥32.91 loss per share (further deteriorated from JP¥10.02 loss in FY 2021). Net loss: JP¥1.95b (loss widened 235% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.お知らせ • Oct 29StemRIM to Report Q1, 2023 Results on Dec 14, 2022StemRIM announced that they will report Q1, 2023 results on Dec 14, 2022お知らせ • Sep 10StemRIM, Annual General Meeting, Oct 26, 2022StemRIM, Annual General Meeting, Oct 26, 2022.Reported Earnings • Sep 10Full year 2022 earnings released: JP¥32.91 loss per share (vs JP¥10.02 loss in FY 2021)Full year 2022 results: JP¥32.91 loss per share (further deteriorated from JP¥10.02 loss in FY 2021). Net loss: JP¥1.95b (loss widened 235% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.お知らせ • Aug 07StemRIM to Report Fiscal Year 2022 Results on Sep 08, 2022StemRIM announced that they will report fiscal year 2022 results on Sep 08, 2022Reported Earnings • Jun 11Third quarter 2022 earnings released: JP¥8.31 loss per share (vs JP¥8.82 loss in 3Q 2021)Third quarter 2022 results: JP¥8.31 loss per share (up from JP¥8.82 loss in 3Q 2021). Revenue: JP¥0 (flat on 3Q 2021). Net loss: JP¥493.0m (loss narrowed 4.8% from 3Q 2021). Profit margin: (in line with 3Q 2021).Price Target Changed • Apr 27Price target increased to JP¥1,400Up from JP¥1,200, the current price target is provided by 1 analyst. New target price is 91% above last closing price of JP¥733. Stock is down 8.4% over the past year. The company posted a net loss per share of JP¥10.02 last year.お知らせ • Jan 28StemRIM to Report Q2, 2022 Results on Mar 10, 2022StemRIM announced that they will report Q2, 2022 results on Mar 10, 2022Reported Earnings • Dec 14First quarter 2022 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2022 results: JP¥8.31 loss per share (down from JP¥4.58 loss in 1Q 2021). Revenue: JP¥22.0m (down 90% from 1Q 2021). Net loss: JP¥490.0m (loss widened 88% from 1Q 2021). Revenue was in line with analyst estimates.Reported Earnings • Nov 02Full year 2021 earnings released: JP¥10.02 loss per share (vs JP¥6.43 profit in FY 2020)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2021 results: Revenue: JP¥1.40b (down 33% from FY 2020). Net loss: JP¥582.0m (down 268% from profit in FY 2020).Price Target Changed • Oct 01Price target increased to JP¥1,000Up from JP¥900, the current price target is provided by 1 analyst. New target price is 47% above last closing price of JP¥682. Stock is down 20% over the past year.Reported Earnings • Sep 15Full year 2021 earnings released: JP¥10.02 loss per share (vs JP¥6.43 profit in FY 2020)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2021 results: Revenue: JP¥1.40b (down 33% from FY 2020). Net loss: JP¥582.0m (down 268% from profit in FY 2020).Price Target Changed • Apr 27Price target decreased to JP¥1,250Down from JP¥1,350, the current price target is provided by 1 analyst. New target price is 58% above last closing price of JP¥792. Stock is up 70% over the past year.Is New 90 Day High Low • Feb 22New 90-day high: JP¥830The company is up 1.0% from its price of JP¥825 on 24 November 2020. The Japanese market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period.お知らせ • Feb 04StemRIM to Report Q2, 2021 Results on Mar 11, 2021StemRIM announced that they will report Q2, 2021 results on Mar 11, 2021Is New 90 Day High Low • Dec 22New 90-day low: JP¥624The company is down 34% from its price of JP¥950 on 23 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 6.0% over the same period.Is New 90 Day High Low • Dec 07New 90-day low: JP¥751The company is down 14% from its price of JP¥873 on 08 September 2020. The Japanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period.お知らせ • Aug 03StemRIM to Report Fiscal Year 2020 Results on Sep 11, 2020StemRIM announced that they will report fiscal year 2020 results on Sep 11, 2020 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、StemRIM は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TSE:4599 - アナリストの将来予測と過去の財務データ ( )JPY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数4/30/2026N/A-1,869N/AN/AN/A1/31/2026N/A-1,809-1,460-1,457N/A10/31/2025N/A-1,897N/AN/AN/A7/31/2025N/A-1,929-1,457-1,414N/A4/30/2025N/A-1,972N/AN/AN/A1/31/2025N/A-2,065-1,577-1,533N/A10/31/2024N/A-2,115N/AN/AN/A7/31/2024N/A-2,022-1,885-1,881N/A4/30/2024N/A-2,131N/AN/AN/A1/31/20242,350179608610N/A10/31/20232,350214N/AN/AN/A7/31/20232,3501681,1351,135N/A4/30/20232,350332N/AN/AN/A1/31/2023N/A-1,957-1,428-1,428N/A10/31/2022N/A-1,971N/AN/AN/A7/31/202222-1,948-1,404-1,404N/A4/30/20221,212-788N/AN/AN/A1/31/20221,212-813-356-295N/A10/31/20211,212-811N/AN/AN/A7/31/20211,400-582-608-519N/A4/30/20211,910-501N/AN/AN/A1/31/20212,3108914191N/A10/31/20202,310358N/AN/AN/A7/31/20202,100347423575N/A4/30/2020400-662N/AN/AN/A7/31/2019100-721N/A-777N/A7/31/2018200-323N/AN/AN/A7/31/2017300-123N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 4599の予測収益成長が 貯蓄率 ( 0.8% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 4599の収益がJP市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 4599の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 4599の収益がJP市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 4599の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 4599の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/06 12:23終値2026/07/06 00:00収益2026/04/30年間収益2025/07/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋StemRIM 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Kyoichiro ShigemuraNomura Securities Co. Ltd.Hiroyuki MatsubaraNomura Securities Co. Ltd.Kota MaedaNomura Securities Co. Ltd.
Price Target Changed • Mar 14Price target decreased by 25% to JP¥900Down from JP¥1,200, the current price target is provided by 1 analyst. New target price is 57% above last closing price of JP¥574. Stock is down 47% over the past year. The company is forecast to post a net loss per share of JP¥21.20 compared to earnings per share of JP¥2.80 last year.
お知らせ • Jun 19StemRIM Provides Earnings Guidance for the Year Ending July 31, 2023StemRIM provided earnings guidance for the year ending July 31, 2023. The company expects operating revenue of ¥2,350 million, operating income of ¥146 million, net income of ¥170 million or ¥2.84 per share.
Price Target Changed • Nov 16Price target increased to JP¥1,240Up from JP¥1,000, the current price target is provided by 1 analyst. New target price is 35% above last closing price of JP¥920. Stock is up 68% over the past year. The company posted a net loss per share of JP¥32.91 last year.
Price Target Changed • Apr 27Price target increased to JP¥1,400Up from JP¥1,200, the current price target is provided by 1 analyst. New target price is 91% above last closing price of JP¥733. Stock is down 8.4% over the past year. The company posted a net loss per share of JP¥10.02 last year.
Price Target Changed • Oct 01Price target increased to JP¥1,000Up from JP¥900, the current price target is provided by 1 analyst. New target price is 47% above last closing price of JP¥682. Stock is down 20% over the past year.
Price Target Changed • Apr 27Price target decreased to JP¥1,250Down from JP¥1,350, the current price target is provided by 1 analyst. New target price is 58% above last closing price of JP¥792. Stock is up 70% over the past year.
分析記事 • Jun 18We're Not Very Worried About StemRIM's (TSE:4599) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...
お知らせ • Jun 17StemRIM Announces Patent Registration (Australia) for Redasemtide, as an Additional Therapeutic Indication of Cartilage DisordersStemRIM Inc. announced that a patent will soon be registered in Australia for the application related to the novel treatment of cartilage disorders (namely traumatic cartilage defect of joint, osteoarthritis, and osteochondritis dissecans) utilizing the peptide drug developed from the "Regeneration-Inducing MedicineTM" development candidate Redasemtide (HMGB1 fragment peptide). Title of Invention Therapeutic agent for cartilage disorder. Region Australia. Application No. 2019367943. Registration No. To be determined . Applicant StemRIM, Osaka University This patent is intended to expand the indications for Redasemtide, which is currently under development, and believe that the granting of this patent will ensure the possibility of developing a drug for cartilage disorders (namely traumatic cartilage defect of joint, osteoarthritis, and osteochondritis dissecans) in Australia. Cartilage disorders cause pain and functional impairment of the joint due to damage or degeneration of cartilage. Because cartilage has limited selfrepair capacity, such disorders tend to become chronic and progressive. It has been confirmed that intravenous administration of Redasemtide mobilizes bone marrow-derived mesenchymal stem cells (MSCs) into the bloodstream and promotes their accumulation at sites of tissue injury. Through this mechanism, Redasemtide is considered to facilitate tissue repair and regeneration in areas of cartilage damage within the knee joint. With its intravenous route of administration, which imposes a relatively low burden on patients, Redasemtide is anticipated to serve as a highly useful therapeutic option in clinical practice.
お知らせ • Jun 16StemRIM Inc Announces Patent Registration In Russia For Redasemtide As Therapeutic Drug For Fatty Liver And Non-Alcoholic SteatohepatitisStemRIM Inc. announced that a medical use patent for the Regeneration-Inducing MedicineTM development candidate, Redasemtide, indicated for fatty liver and non-alcoholic steatohepatitis, will soon be registered in Russia. Title of Invention: Therapeutic drug for fatty liver and non-alcoholic steatohepatitis. Region: Russia. Application No.: 2024111536. Registration No.: To be determined. Applicant: StemRIM Inc., Osaka University, Niigata University. This patent is intended to expand the indications for Redasemtide, which is currently under development. Fatty liver is a condition in which excess fat accumulates in the liver. Non-alcoholic steatohepatitis (NASH) is a progressive fatty liver disease caused by factors other than alcohol consumption characterized by inflammation and fibrosis of the liver, which, if left untreated, can lead to cirrhosis or liver cancer. Both fatty liver and NASH are expected to see an increase in patient numbers due to the rising prevalence of obesity and diabetes. However, there are currently no effective drug treatments available, and dietary and exercise therapy remain the main approaches. The development of new therapeutic drugs and regenerative medicine is urgently needed. The impact on the financial performance for the fiscal year ending July 31, 2026, is insignificant. The terms "fatty liver" and "non-alcoholic steatohepatitis (NASH)" have been renamed to "steatotic liver disease (SLD)" and "metabolic dysfunction associated steatohepatitis (MASH)," respectively.
New Risk • Mar 11New major risk - Revenue and earnings growthEarnings have declined by 30% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 30% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (6.7% average weekly change).
New Risk • Jan 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.3b net loss in 3 years). Share price has been volatile over the past 3 months (5.4% average weekly change).
お知らせ • Jan 06StemRIM to Report Q2, 2026 Results on Mar 11, 2026StemRIM announced that they will report Q2, 2026 results on Mar 11, 2026
New Risk • Dec 15New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥15.5b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.3b net loss in 3 years). Market cap is less than US$100m (JP¥15.5b market cap, or US$99.9m).
Board Change • Nov 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. Founder, Chief Scientific Officer & Director Katsuto Tamai was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Oct 28StemRIM to Report Q1, 2026 Results on Dec 10, 2025StemRIM announced that they will report Q1, 2026 results on Dec 10, 2025
お知らせ • Sep 10StemRIM, Annual General Meeting, Oct 22, 2025StemRIM, Annual General Meeting, Oct 22, 2025.
お知らせ • Aug 09StemRIM to Report Fiscal Year 2025 Results on Sep 10, 2025StemRIM announced that they will report fiscal year 2025 results on Sep 10, 2025
お知らせ • Jun 03StemRIM to Report Q3, 2025 Results on Jun 11, 2025StemRIM announced that they will report Q3, 2025 results on Jun 11, 2025
Board Change • May 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Outside Director Noriko Sawai was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Apr 09We're Interested To See How StemRIM (TSE:4599) Uses Its Cash Hoard To GrowEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • Apr 02StemRIM Inc. Announces the Interim Analysis Results for the Global Phase 2B Clinical Trial in Patients with Acute Ischemic StrokeStemRIM Inc. announced that the interim analysis results for the global Phase 2b clinical trial of Redasemtide, which was previously out-licensed from company to Shionogi & Co. Ltd. for the treatment of acute ischemic stroke (AIS). This clinical trial is being conducted in 18 countries worldwide, including Japan, the United States, and Europe, to evaluate the efficacy and safety of Redasemtide in AIS patients who are not eligible for endovascular recanalization therapy. The trial consists of 3 cohorts, with patients receiving Redasemtide at a dose of 1.5 mg/kg, Redasemtide at an dose of 0.75 mg/kg, or a placebo for 5 days. With advances in medical technology, the treatment paradigm for AIS has undergone significant changes, and the proportion of patients eligible for treatment with endovascular recanalisation therapy has been rapidly increasing. To adapt to these changes and enable broader patient access to Redasemtide after its market approval, conducted an interim futility analysis by dose group in AIS patients for whom endovascular reperfusion therapy could not be performed. In this interim analysis, a predefined futility criterion was established. For each dose group, if the results met the futility criterion compared to the placebo group, the study would be discontinued for that group; if not, it would be continued. To maintain blinding, an independent evaluation committee assessed the data and provided recommendations to Shionogi regarding the continuation or discontinuation of each dose group. While Redasemtide (1.5 mg/kg) group was originally selected as the expected efficacious dose at the start of the trial, the inclusion of Redasemtide (0.75 mg/kg) group was mandated by regulatory authorities. The outcome of this interim analysis falls within the anticipated range. With the discontinuation of the lower dose group, the required number of subjects will be reduced, and further progress in the study is expected moving forward. Going forward, the target number of subjects will be redefined to include the additional cohort; however, the overall study duration is not expected to be extended. The results of this interim analysis hold significant importance in the clinical development of this investigational drug for AIS, and the company are very pleased with the outcome. At this time, there is no impact on the financial results for the fiscal year ending July 31, 2025.
New Risk • Mar 11New major risk - Revenue and earnings growthEarnings have declined by 31% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 31% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (5.9% average weekly change).
お知らせ • Jan 30StemRIM to Report Q2, 2025 Results on Mar 12, 2025StemRIM announced that they will report Q2, 2025 results on Mar 12, 2025
New Risk • Dec 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Earnings are forecast to decline by an average of 1.8% per year for the foreseeable future. Minor Risk Share price has been volatile over the past 3 months (5.4% average weekly change).
お知らせ • Oct 29StemRIM to Report Q1, 2025 Results on Dec 11, 2024StemRIM announced that they will report Q1, 2025 results on Dec 11, 2024
分析記事 • Oct 04StemRIM (TSE:4599) Is In A Strong Position To Grow Its BusinessEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • Sep 11StemRIM, Annual General Meeting, Oct 30, 2024StemRIM, Annual General Meeting, Oct 30, 2024.
お知らせ • Jul 27StemRIM to Report Fiscal Year 2024 Results on Sep 11, 2024StemRIM announced that they will report fiscal year 2024 results on Sep 11, 2024
New Risk • Jun 17New major risk - Revenue sizeThe company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (JP¥1.7b net loss in 3 years). Share price has been volatile over the past 3 months (5.6% average weekly change). Shareholders have been diluted in the past year (2.5% increase in shares outstanding).
お知らせ • Apr 03StemRIM to Report Q3, 2024 Results on Jun 12, 2024StemRIM announced that they will report Q3, 2024 results on Jun 12, 2024
分析記事 • Mar 20StemRIM's (TSE:4599) Earnings Seem To Be PromisingThe market seemed underwhelmed by the solid earnings posted by StemRIM ( TSE:4599 ) recently. Our analysis suggests...
Price Target Changed • Mar 14Price target decreased by 25% to JP¥900Down from JP¥1,200, the current price target is provided by 1 analyst. New target price is 57% above last closing price of JP¥574. Stock is down 47% over the past year. The company is forecast to post a net loss per share of JP¥21.20 compared to earnings per share of JP¥2.80 last year.
お知らせ • Mar 13StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic CardiomyopathyStemRIM Inc. announced that a clinical trial plan for Phase 2 investigator-initiated clinical trial, targeting ischemic cardiomyopathy using Redasemtide, has been submitted to the Pharmaceuticals and Medical Devices Agency (PMDA) by Osaka University. Redasemtide is a drug under development that has been licensed out to Shionogi & Co. Ltd. This clinical trial will be initiated with the submission of this clinical trial plan notification. This clinical trial will be conducted as an investigator-initiated clinical trials at Osaka University Hospital and several other facilities. The main objective of this clinical trial is to evaluate the efficacy and safety of Redasemtide in patients with ischemic cardiomyopath who have undergone coronary artery bypass grafting. This clinical trial will evaluate various cardiac function tests such as echocardiography at 52 weeks after treatment with either Redasemtide or placebo (10 patients each) for 5 days. Redasemtide are a completely new concept in medicine that induces functional regeneration of organs and tissues damaged by injury or disease. The ectodermal mesenchymal stem cells induced by administration of Redasemtide can differentiate into diverse tissues and are expected to be effective in a variety of disease areas, including ischemic cardiomyiology. Furthermore, as it is administered through intravenous infusion and does not involve the use of live cells, this pharmaceutical product is industrially producible. Unlike traditional regenerative medical products that utilize live cells, it avoids quality control issues during manufacturing and product transport. It is anticipated to have a cost advantage and widespread adoption due to its simple administration method. In clinical trials to date, the safety and efficacy of Redasemtide have been confirmed in dystrophic epidermolysis bullosa (add additional Phase 2 clinical trial ongoing at Osaka University Hospital and other institutions), acute ischemic stroke (global Phase 2b clinical trial ongoing in Japan, the United States, and Europe), knee osteoarthritis (Phase 2 investigator-initiatedclinical trial completed at Hirosaki University Hospital), and chronic liver disease (Phase 2 investigator-in initiated clinical trial l completed at Niigata University Medical and Dental Hospital). Ischemic cardiomyopathy will be the 5th indication for Redasemtide in a Phase 2 clinical trial. The impact on the financial performance for the fiscal year ending July 31, 2024, is nothing. Nevertheless, believe it contributes to the medium to long-term improvement of overall performance.
お知らせ • Feb 01StemRIM Inc. Announces Patent Registration (Russia) for the Use of the HMGB1 Fragment Peptide, as an Additional Therapeutic Indication of Cartilage DisordersStemRIM Inc. announced that a patent has been registered in Russia for the application related to the novel treatment of cartilage disorders (traumatic cartilage deficiency syndrome, osteoarthritis, disseverance osteochondritis, etc.) utilizing the peptide drug developed from the "Regeneration-Inducing MedicineTM" development candidate Redasemtide (HMGB1 fragment peptide). Title of Invention: Therapeutic agent for traumatic cartilage deficiency syndrome, osteearthritis, disseverance Osteochondritis. Region.: Russia. Application No. 2021114359. Registration No. To be determined. Applicant. StemRIM, Osaka University. This patent is intended to expand the indications for Redasemtide, which is currently under development, and believe that the granting of this patent will ensure the possibility of developing a drug for cartilage disorders (traumatic cart cartilage deficiency syndrome, osteOarthritis, disseverance boneochondritis, etc.) in Russia. To date, the company have been granted many patents for HMGB1 fragment peptides (including Redasemtide) in Japan, the U.S., Europe, and other countries around the world, including substance patents and medical use patents. The impact on the financial performance for the fiscal year ending July 31, 2024, is insignificant.
お知らせ • Jan 28StemRIM to Report Q2, 2024 Results on Mar 13, 2024StemRIM announced that they will report Q2, 2024 results on Mar 13, 2024
お知らせ • Oct 29StemRIM to Report Q1, 2024 Results on Dec 13, 2023StemRIM announced that they will report Q1, 2024 results on Dec 13, 2023
お知らせ • Sep 13StemRIM, Annual General Meeting, Oct 25, 2023StemRIM, Annual General Meeting, Oct 25, 2023.
お知らせ • Sep 05StemRIM Announces Patent Registration (China) for the Use of Redasemtide as an Additional Treatment for Cardiomyopathy and Old Myocardial InfarctionStemRIM announces that a medical use patent for the "Regeneration- Inducing MedicineTM" development candidate, Redasemtide, indicated for cardiomyopathy, old myocardial infarction, and chronic heart failure associated with them, will soon be registered in China. This patent is intended to expand the indications for Redasemtide, which is currently underdevelopment, and believe that the granting of this patent will ensure the possibility of developing a drug for cardiomyopathy, old myocardial infarction, and chronic heart failure inChina. To date, it have been granted many patents for HMGB1 fragment peptides (including Redasemtide) in Japan, the U.S., Europe, and other countries around the world, including substance patents and medical use patents. The impact on the financial performance for the fiscal year ending July 31, 2024, is insignificant.
お知らせ • Aug 01StemRIM Inc. Announces the First Administration of Global Late Phase 2 Clinical Trials for Redasemtide Targeting Acute Ischemic Stroke (Japan)StemRIM Inc. announced that Shionogi & Co. Ltd. has notified that the first patient has been administered of the global late phase 2 clinical trial for Redasemtide targeting acute ischemic stroke in Japan. This clinical trial is a global late phase 2 clinical trial, planned to be conducted in 19 countriesworldwide, including Japan, the United States, and Europe. It aims to evaluate the effectiveness and safety of administering Redasemtide to 627 patients with acute ischemic stroke, aged 18 years and above, within 25 hours of symptom onset.
お知らせ • Jul 26StemRIM Inc. Announces Commencement of Global Late Phase 2 Clinical Trial for Redasemtide in Patients with Acute Ischemic Stroke in the Europe and ChinaStemRIM Inc. announced the commencement, from July 25, 2023, of a global late Phase 2 clinical trial for Redasemtide in patients with acute ischemic stroke in the Europe and China. Shionogi &Co. Ltd. submitted the Clinical Trial Plan Notification for the global Phase 2 clinical trial to the European Medicines Agency on March 31, 2023, and to the National Medical Products Administration in China on April 28, 2023. Originally, a global Phase 3 trial was planned, but a global late Phase 2 trial was chosen instead for dose setting. The trial has already been underway in Japan and the United States, and it has just started in Europe and China. This development is progressing as planned and is not expected to have any impact on the financial performance for the fiscal year ending July 31, 2023. However, the company believe that it will contribute to the improvement of its performance in the medium to long term.
お知らせ • Jul 22StemRIM to Report Fiscal Year 2023 Results on Sep 13, 2023StemRIM announced that they will report fiscal year 2023 results on Sep 13, 2023
お知らせ • Jun 19StemRIM Provides Earnings Guidance for the Year Ending July 31, 2023StemRIM provided earnings guidance for the year ending July 31, 2023. The company expects operating revenue of ¥2,350 million, operating income of ¥146 million, net income of ¥170 million or ¥2.84 per share.
Reported Earnings • Jun 16Third quarter 2023 earnings released: EPS: JP¥31.50 (vs JP¥8.31 loss in 3Q 2022)Third quarter 2023 results: EPS: JP¥31.50 (up from JP¥8.31 loss in 3Q 2022). Net income: JP¥1.80b (up JP¥2.29b from 3Q 2022). Revenue is expected to decline by 40% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Japan are expected to grow by 9.1%. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings.
お知らせ • Jan 06StemRIM to Report Q2, 2023 Results on Mar 08, 2023StemRIM announced that they will report Q2, 2023 results on Mar 08, 2023
Price Target Changed • Nov 16Price target increased to JP¥1,240Up from JP¥1,000, the current price target is provided by 1 analyst. New target price is 35% above last closing price of JP¥920. Stock is up 68% over the past year. The company posted a net loss per share of JP¥32.91 last year.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Outside Director Tadahiro Nagai was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Nov 11Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Outside Director Tadahiro Nagai was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 02Full year 2022 earnings released: JP¥32.91 loss per share (vs JP¥10.02 loss in FY 2021)Full year 2022 results: JP¥32.91 loss per share (further deteriorated from JP¥10.02 loss in FY 2021). Net loss: JP¥1.95b (loss widened 235% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
お知らせ • Oct 29StemRIM to Report Q1, 2023 Results on Dec 14, 2022StemRIM announced that they will report Q1, 2023 results on Dec 14, 2022
お知らせ • Sep 10StemRIM, Annual General Meeting, Oct 26, 2022StemRIM, Annual General Meeting, Oct 26, 2022.
Reported Earnings • Sep 10Full year 2022 earnings released: JP¥32.91 loss per share (vs JP¥10.02 loss in FY 2021)Full year 2022 results: JP¥32.91 loss per share (further deteriorated from JP¥10.02 loss in FY 2021). Net loss: JP¥1.95b (loss widened 235% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
お知らせ • Aug 07StemRIM to Report Fiscal Year 2022 Results on Sep 08, 2022StemRIM announced that they will report fiscal year 2022 results on Sep 08, 2022
Reported Earnings • Jun 11Third quarter 2022 earnings released: JP¥8.31 loss per share (vs JP¥8.82 loss in 3Q 2021)Third quarter 2022 results: JP¥8.31 loss per share (up from JP¥8.82 loss in 3Q 2021). Revenue: JP¥0 (flat on 3Q 2021). Net loss: JP¥493.0m (loss narrowed 4.8% from 3Q 2021). Profit margin: (in line with 3Q 2021).
Price Target Changed • Apr 27Price target increased to JP¥1,400Up from JP¥1,200, the current price target is provided by 1 analyst. New target price is 91% above last closing price of JP¥733. Stock is down 8.4% over the past year. The company posted a net loss per share of JP¥10.02 last year.
お知らせ • Jan 28StemRIM to Report Q2, 2022 Results on Mar 10, 2022StemRIM announced that they will report Q2, 2022 results on Mar 10, 2022
Reported Earnings • Dec 14First quarter 2022 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2022 results: JP¥8.31 loss per share (down from JP¥4.58 loss in 1Q 2021). Revenue: JP¥22.0m (down 90% from 1Q 2021). Net loss: JP¥490.0m (loss widened 88% from 1Q 2021). Revenue was in line with analyst estimates.
Reported Earnings • Nov 02Full year 2021 earnings released: JP¥10.02 loss per share (vs JP¥6.43 profit in FY 2020)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2021 results: Revenue: JP¥1.40b (down 33% from FY 2020). Net loss: JP¥582.0m (down 268% from profit in FY 2020).
Price Target Changed • Oct 01Price target increased to JP¥1,000Up from JP¥900, the current price target is provided by 1 analyst. New target price is 47% above last closing price of JP¥682. Stock is down 20% over the past year.
Reported Earnings • Sep 15Full year 2021 earnings released: JP¥10.02 loss per share (vs JP¥6.43 profit in FY 2020)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2021 results: Revenue: JP¥1.40b (down 33% from FY 2020). Net loss: JP¥582.0m (down 268% from profit in FY 2020).
Price Target Changed • Apr 27Price target decreased to JP¥1,250Down from JP¥1,350, the current price target is provided by 1 analyst. New target price is 58% above last closing price of JP¥792. Stock is up 70% over the past year.
Is New 90 Day High Low • Feb 22New 90-day high: JP¥830The company is up 1.0% from its price of JP¥825 on 24 November 2020. The Japanese market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period.
お知らせ • Feb 04StemRIM to Report Q2, 2021 Results on Mar 11, 2021StemRIM announced that they will report Q2, 2021 results on Mar 11, 2021
Is New 90 Day High Low • Dec 22New 90-day low: JP¥624The company is down 34% from its price of JP¥950 on 23 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 6.0% over the same period.
Is New 90 Day High Low • Dec 07New 90-day low: JP¥751The company is down 14% from its price of JP¥873 on 08 September 2020. The Japanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period.
お知らせ • Aug 03StemRIM to Report Fiscal Year 2020 Results on Sep 11, 2020StemRIM announced that they will report fiscal year 2020 results on Sep 11, 2020